Latest Content

Real-world enfortumab vedotin dose reductions reduced treatment interruptions without significantly affecting OS in advanced urothelial carcinoma.

Pelareorep has received FDA fast track designation in combination with SOC bevacizumab and FOLFIRI in the second line for KRAS-mutant MSS mCRC.

MD Anderson data scientist Iakovos Toumazis, PhD, will further IDSO's goal to bring data science to inform decision-making for cancer control and public health.

Northwell’s Louis Potters, MD, discusses how treatment directives improve safety, consistency, and equity in cancer care in honor of World Cancer Day.

In case you missed any, read a recap of the episodes of OncLive On Air that aired in January 2026.

Sandip P. Patel, MD, discusses how AI can be used to improve clinical trial design and accrual.

Ryan D. Chow, MD, PhD, Ronac Mamtani, MD, MSCE, and Ramy Sedhom, MD, spotlight a real-world analysis of upfront enfortumab vedotin dose reduction in bladder cancer.

The FDA granted priority review to Dato-DXd for patients with first-line unresectable or metastatic TNBC who are not eligible to receive immunotherapy.

Tagraxofusp was well tolerated and yielded modest efficacy signals as monotherapy in myelofibrosis.

Maurie Markman, MD, discusses the role of the individual vs the multidisciplinary team in cancer care.

The American Cancer Society has released their annual Cancer Facts & Figures and Cancer Statistics reports.

Ahead of the 2026 Transplantation & Cellular Therapy Meetings, experts preview data on CAR T-cell therapy efficacy, donor access, and toxicity mitigation.

PRV211 was safe with no SAEs, systemic toxicities, or DLTs for the treatment of patients with invasive oral cavity cancer.